Biologics

Biologics
Product Description

Why have we developed our bio nanoparticle technology?

The biologics industry is expanding rapidly as the potential of biological therapies grows in recognition. The field is also expected to become more versatile as it grows from antibody-focused production to gene and cell therapies, exosomes, fusion proteins and nanotechnology approaches. However, despite their success so far, biologics come with a number of challenges.

Among these is that the production cost of biologics is high. Despite this, increased opportunities for patient centricity exist, including better formulations and different modes of administration to aid drug delivery. Direct nanoforming of biologics is a promising new approach to allow more life-changing large-molecule drugs to reach the market, which was a key driving force behind the development of our proprietary biological technology.

Our technology

Our biological nanoforming technology can deliver large-molecule drug particles as small as 50 nm while retaining biological activity. It’s effectiveness has been demonstrated on proteins in the 6 kDa – 140 kDa range, and it is capable of engineering particle sizes to specific requirements. Our advanced technology can be applied across the biologics field to potentially:

Change delivery routes

Increase uptake

Enable new drug combinations

Tailor release profiles

Enhance drug loading capacity in formulations

Implement lighter infrastructures for drug logistics

Nanoform Finland Oy

  • FI
  • 2019
    On CPHI since
  • 1
    Certificates
  • 100 - 249
    Employees
Company types
Other

Nanoform Finland Oy

  • FI
  • 2019
    On CPHI since
  • 1
    Certificates
  • 100 - 249
    Employees
Company types
Other

More Products from Nanoform Finland Oy (3)

  • AI Drug Candidate Screening

    Product AI Drug Candidate Screening

    Our STARMAP® 2.0 platform leverages cutting-edge sparse-data AI to pick winners among candidate molecules that are predicted to be best amenable to CESS®-powered nanoforming and that exhibit optimal production characteristics.

    When existing data alone is not sufficient for generating specific pr...
  • Formulations

    Product Formulations

    We understand that speed is of the essence when working to deliver a life-changing drug to market. Our experienced clinical formulation development team can support formulation development across a vast range of dosage forms – including oral, ophthalmic and transdermal formulations, as well as injectables,...
  • Small Molecules

    Product Small Molecules

    Our multi-patented Controlled Expansion of Supercritical Solutions (CESS®) technology enables the creation of API nanoparticles directly from solution. The process can be applied to most small molecules, with a high success rate of 80-90%.

    CESS® is a bottom-up method of recrystallization that wo...

Nanoform Finland Oy resources (3)

  • Brochure Nanoform launches next-generation STARMAP ®️ v2.0, the AI-based drug candidate selection tool for CESS ®️

    The technology utilizes sparse-data AI to augment experimental results from its CESS®️ nanoparticle engineering process with detailed expert knowledge, allowing reliable predictions to be made regarding partners’ potential success of nanoforming their drug molecules.
  • Whitepaper Transforming drug development with nanoparticle engineering

    This white paper delves into current technological innovations in nanoparticle engineering that aim to increase the number of drugs reaching the market.
  • Video Overcoming Drug Development Challenges with Nanotechnology

    This webinar originally aired as part of CPHI Discover - 17-28 May 2021 This session will focus on the application of nanotechnology to drug development, examining several areas of opportunity where current and emerging nanotechnologies could enable entirely novel classes of therapeutics. Gain perspective on the current status and the future growth and success of the field. New promising nanotechnology platforms to overcome drug development challenges to rapidly progress novel drugs to market. Specific applications of emerging interest in nanotechnology-based drug development systems The potential impact of Nanotechnology on the development of Personalized Medicine Increasing the possibilities and probabilities for Pharma using STARMAP AI technology Frontrunners within the particle engineering space - CESS® vs the rest Positive data from the first-in-human trial of a Nano-formed drug